pipeline | autoimmune/inflammation | oncology
A Phase I healthy volunteer study for ALPN-101 is currently enrolling. ALPN-202 is targeted to file an IND later in 2019.
Congrats on the launch of the SURPASS trial!
July 18, 2019 6:36 pm
We are presenting at the JMP Securities Life Science Conference later today at 1:30pm EDT. To hear the presentation… twitter.com/i/web/status/11417…
June 20, 2019 6:01 pm
© 2019 Alpine Immune Sciences.
All Rights Reserved, Alpine Immune Sciences Inc.